In some embodiments provided herein is a method of treating pain associated with cesarean section surgery in a subject, the method comprising administering into the subject a pharmaceutical composition comprising: a) a multivesicular liposome comprising: at least one amphipathic lipid, and at least one neutral lipid; and b) an aqueous phase comprising bupivacaine phosphate, wherein the aqueous phase is encapsulated within the multivesicular liposome.

The present disclosure application relates to cannabis-containing compositions comprising at least one cannabinoid, provided in a gel formulation. The compositions may include cannabidiol. The source of the cannabidioid may be cannabis, a cannabis extract, or an industrial hemp oil extract. Methods of treating and/or reducing symptoms of an inflammatory response and/or inflammation are described, comprising administering to a subject in need thereof the disclosed compositions.

Described is a method of manufacturing carboxymethyl cellulose (CMC) fibres containing an antimicrobial, the fibres being suitable for use in the preparation of wound dressings, wherein the antimicrobial is selected from the group consisting of a biguanide, a biguanide derivative, octenidine, taurolidine, and a combination of two or more thereof, the method comprising, submerging CMC fibres comprising at least 95 wt % carboxymethylcellulose on a dry weight basis in a treatment solution for a duration adequate to provide the CMC fibres containing an antimicrobial, the treatment solution comprising the antimicrobial and at least 70 wt % of a water-miscible organic solvent selected from C.sub.1-C.sub.4 alkanols, C.sub.3-C.sub.5 ketones, and a combination of two or more thereof. Anti-microbial CMC fibres obtained by the methods and wound dressings containing such fibres are also described.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

A composition comprising or consisting of L-theanine and one or more fructooligosaccharides, wherein the ratio of L-theanine to froctooligosaccharide(s) is of about 2:1 to 99:1. A composition in the form of a food or nutraceutical, and also in the form of a powder, granules, suspension, tablet, capsule, lozenge, bakery item, sweets, drink, beverage or oral preparation.

A composition comprising or consisting of L-theanine and one or more fructooligosaccharides, wherein the ratio of L-theanine to froctooligosaccharide(s) is of about 2:1 to 99:1. A composition in the form of a food or nutraceutical, and also in the form of a powder, granules, suspension, tablet, capsule, lozenge, bakery item, sweets, drink, beverage or oral preparation.

This disclosure relates to new phthalimide and isoindolinone derivatives and other PFKFB3 inhibitors for use in the treatment of diseases. The invention further relates to pharmaceutical compositions containing such PFKFB3 inhibitors, methods of preparation thereof, methods for their use as therapeutic agents, and methods of preparation of a medicament for use in therapy, as well as kits and other inventions comprising such PFKFB3 inhibitors. These PFKFB3 inhibitors are useful for the treatment and prophylaxis of cancer, neurodegenerative diseases, autoimmune diseases, inflammatory disorders, multiple sclerosis, metabolic diseases, inhibition of angiogenesis and other diseases and conditions, where the modulation of PFKFB3 and/or PFKFB4 has beneficial effect as well as neuroprotection.

Provided herein are compositions including methylene bis[4,4′-(2-chlorophenylureidophenoxyisobutyric acid)] (LR-90) or a pharmaceutically acceptable salt or derivative thereof and methods of use thereof for treating and/or preventing chemotherapy-induced neuropathic pain in a subject in need thereof.

The invention relates to antimicrobial peptides (AMPs). The invention also relates to uses, methods of treatment, pharmaceutical compositions and combinations with antimicrobial agents.